LTX-315

Lytix Biopharma AS plans a private placement raising NOK 90-100M and a retail offering via PrimaryBid up to EUR 1M at NOK 6.00 per share. Proceeds will fund studies, manufacturing, and corporate purposes, extending cash runway through 2025. Pre-commitments total NOK 75M, with additional guarantees ensuring minimum NOK 100M. The private placement targets selected investors, while the PrimaryBid offering is for public in Norway, Denmark, and Finland. Applications open 16-17 December 2024. Allocation and settlement details are provided, with lock-up arrangements and potential subsequent offerings considered.

Lytix Biopharma presented updated results from its basal cell carcinoma study at the DNB Nordic Healthcare conference, showing a 97% overall response rate for LTX-315. The study also reported an 86% tumor size reduction and 51% complete clearance rate. The company aims to advance to phase III, targeting a $11.5 bn global market by 2028.

Lytix Biopharma reports Q3 2024 progress, including positive clinical results in basal cell carcinoma and melanoma, and strategic advancements towards commercialization. LTX-315 shows 86% tumor size reduction in BCC and 40% disease control in melanoma. A new phase II study for early-stage melanoma and an improved LTX-401 formulation are underway. Cash reserves expected to last into 2025.

First patient treated in Phase II trial (NeoLIPA) evaluating Lytix Biopharma's LTX-315 in early-stage melanoma at Radiumhospitalet, Oslo. Combination therapy with LTX-315 and pembrolizumab aims to improve pathologic complete response (pCR) rate and prevent recurrence. Expected interim results in H2 2025.

Lytix Biopharma initiates Phase II NeoLIPA trial treating early-stage melanoma patients with LTX-315 and pembrolizumab before surgery, aiming to improve pathologic complete response rates and prevent disease recurrence.

Lytix Biopharma presents positive LTX-315 data at 2024 Fall Clinical Dermatology Conference, showing 51% tumor cell elimination in BCC patients, with 86% tumor size reduction and no serious adverse events. Verrica Pharmaceuticals plans to finalize Phase II study in H1 2025 and discuss next steps with FDA.